The proton pump inhibitors (PPIs) market is expected to witness substantial growth during the forecast period. Surge in prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and helicobacter pylori infections are key factors bolstering the proton pump inhibitors (PPIs) industry growth.
Furthermore, aging populations across the world, dietary habits, and various lifestyle changes also contribute to market progress. The overall market is dominated by several key players that are involved in manufacturing proton pump inhibitor medications.
Growth in awareness about gastrointestinal disorders and improvement in healthcare infrastructure in emerging markets present lucrative proton pump inhibitors (PPIs) market opportunities to manufacturers. Expansion into emerging regions entails adaptation to local regulations, pricing dynamics, and consumer preferences.
Proton pump inhibitors play a vital role in preventing acid-related disorders of the gastrointestinal tract.
Proton pump inhibitors are medicines majorly prescribed for the treatment of GERD, peptic ulcers, helicobacter pylori infections, and other acid-related disorders.
These medications block the gastric hydrogen potassium ATPase or H+/K+ ATPase and inhibit gastric acid secretion in the stomach, providing relief from symptoms such as heartburn, acid reflux, and abdominal pain.
Proton pump inhibitors are the most common prescribed drug to reduce stomach acid, which in excess, can inflame or irritate the esophagus and cause heartburn or peptic ulcers.
| Attribute | Detail |
|---|---|
| Drivers |
|
The prevalence of gastrointestinal disorders has globally increased due to factors such as poor dietary choices, sedentary lifestyles, stress, and an aging population. Diets high in fat, spice, and acidity, along with irregular eating patterns, can potentially lead to acid reflux and digestive issues.
During the COVID-19 pandemic it was reported that the percentage of patients suffering from symptoms associated with gastrointestinal disorders increased as compared with the patients before the pandemic.
According to research conducted by mytotalhealthinc.com in April 2020, out of 71,812 participants, 44.1% reported past GERD symptoms and 30.9% experienced symptoms within the past week.
Moreover, 35.1% of those with GERD symptoms were on therapy, with 55.2% using proton pump inhibitors (PPIs). Thus, PPIs have proven beneficial in managing gastrointestinal conditions.
In November 2022, an article published by the Canadian Paediatric Society (CPS) stated that regurgitation or vomiting following most feeds had been reported in 20% of healthy infants at 1 month of age.
This can increase to 41% between 3 and 4 months of age, which then subsequently decreases, becoming rare after 1 year of age. Thus, such a high number of infants suffering from GERD is expected to increase the demand for omeprazole-based drugs and consequently drive the proton pump inhibitors (PPIs) market growth.
Growth in product launches by key players is expected to fuel the overall proton pump inhibitors (PPIs) market value during the forecast period.
Additionally, the surge in product approvals and strong product pipeline of new proton pump inhibitor drugs for GERD and ulcers by key players in the proton pump inhibitor (PPIs) sector are expected to drive overall market statistics during the forecast period
In November 2023, Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that U.S. FDA has approved VOQUENZA (vonoprazan) tablets 10mg and 20mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of Erosive Esophagitis, also known as Erosive GERD (gastroesophageal reflux disease), maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with Erosive GERD.
Furthermore, in September 2022, the U.S. FDA approved Azurity Pharmaceutical’s omeprazole and sodium bicarbonate for oral suspension to treat benign gastric ulcers and it reached commercial markets by 2023. The omeprazole and sodium bicarbonate for oral suspension is a combination of proton pump inhibitor omeprazole (PPI) with sodium bicarbonate.
According to the National Library of Medicine Report published in August 2020, use of proton pump inhibitors can increase the risk of COVID-19. Moreover, individuals using proton pump inhibitors twice daily are more likely to get infected by COVID-19. These factors are proving to be market limitations.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest proton pump inhibitors (PPIs) market analysis, North America dominates the landscape. Advanced healthcare expenditure, including well established clinics and hospitals equipped with modern diagnostic and treatment options are driving market dynamics in the region.
By drug type, the proton pump inhibitors (PPIs) market in North America is dominated by the omeprazole and pantoprazole segments, attributed to the growth in number of visits to physician offices with acid reflux diseases such as GERD and peptic ulcers.
The omeprazole segment holds a slightly higher market share in North America due to the largest number of prescriptions for this drug in the region.
The global proton pump inhibitors (PPIs) market share is fragmented with the presence of a number of players. Companies are engaging in partnerships and collaborations to gain a strong foothold in the market.
Pfizer, Teva Pharmaceutical Industries Ltd. LUPIN Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Sanofi S.A., and AstraZeneca are the prominent proton pump inhibitors (PPIs) market manufacturers.
Key players have been profiled in the proton pump inhibitors (PPIs) market research report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 3.7 Bn |
| Forecast Value in 2034 | More than US$ 5.6 Bn |
| CAGR | 4.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 3.7 Bn in 2023
It is projected to reach more than US$ 5.6 Bn by the end of 2034
The CAGR is anticipated to be 4.0% from 2024 to 2034
North America is expected to account for the largest share from 2024 to 2034
Pfizer, Teva Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Sanofi S.A., and AstraZeneca
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Proton Pump Inhibitors (PPIs) Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecasts, 2020-2034
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Regulatory Scenario
5.2. Product Approval/Launches
5.3. Pipeline Analysis
6. Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020-2034
6.3.1. Omeprazole
6.3.2. Pantoprazole
6.3.3. Esomeprazole
6.3.4. Lansoprazole
6.3.5. Rabeprazole
6.3.6. Others (Dexlansoprazole, etc.)
6.4. Market Attractiveness By Drug Type
7. Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecasts, By Indication Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication Type, 2020-2034
7.3.1. Gastroesophageal Reflux Disease
7.3.2. Peptic Ulcers
7.4. Market Attractiveness By Indication Type
8. Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness By End-user
9. Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Proton Pump Inhibitors (PPIs) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2020-2034
10.2.1. Omeprazole
10.2.2. Pantoprazole
10.2.3. Esomeprazole
10.2.4. Lansoprazole
10.2.5. Rabeprazole
10.2.6. Others (Dexlansoprazole, etc.)
10.3. Market Value Forecast By Indication Type, 2020-2034
10.3.1. Gastroesophageal Reflux Disease
10.3.2. Peptic Ulcers
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast By, 2020-2034
10.6. Market Value Forecast By Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Indication Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Proton Pump Inhibitors (PPIs) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2034
11.2.1. Omeprazole
11.2.2. Pantoprazole
11.2.3. Esomeprazole
11.2.4. Lansoprazole
11.2.5. Rabeprazole
11.2.6. Others (Dexlansoprazole, etc.)
11.3. Market Value Forecast By Indication Type, 2020-2034
11.3.1. Gastroesophageal Reflux Disease
11.3.2. Peptic Ulcers
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast By, 2020-2034
11.6. Market Value Forecast By Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Indication Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Proton Pump Inhibitors (PPIs) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2034
12.2.1. Omeprazole
12.2.2. Pantoprazole
12.2.3. Esomeprazole
12.2.4. Lansoprazole
12.2.5. Rabeprazole
12.2.6. Others (Dexlansoprazole, etc.)
12.3. Market Value Forecast By Indication Type, 2020-2034
12.3.1. Gastroesophageal Reflux Disease
12.3.2. Peptic Ulcers
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast By, 2020-2034
12.6. Market Value Forecast By Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. India
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Indication Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Proton Pump Inhibitors (PPIs) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2034
13.2.1. Omeprazole
13.2.2. Pantoprazole
13.2.3. Esomeprazole
13.2.4. Lansoprazole
13.2.5. Rabeprazole
13.2.6. Others (Dexlansoprazole, etc.)
13.3. Market Value Forecast By Indication Type, 2020-2034
13.3.1. Gastroesophageal Reflux Disease
13.3.2. Peptic Ulcers
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By, 2020-2034
13.6. Market Value Forecast By Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Indication Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Proton Pump Inhibitors (PPIs) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2034
14.2.1. Omeprazole
14.2.2. Pantoprazole
14.2.3. Esomeprazole
14.2.4. Lansoprazole
14.2.5. Rabeprazole
14.2.6. Others (Dexlansoprazole, etc.)
14.3. Market Value Forecast By Indication Type, 2020-2034
14.3.1. Gastroesophageal Reflux Disease
14.3.2. Peptic Ulcers
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast By, 2020-2034
14.6. Market Value Forecast By Country, 2020-2034
14.6.1. GCC
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Indication Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Pfizer
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Teva Pharmaceutical Industries Ltd.
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. LUPIN Limited
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Amneal Pharmaceuticals LLC
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Zydus Cadila
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Sun Pharmaceutical Industries Ltd.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. Alembic Pharmaceuticals Limited
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. Sanofi S.A.
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
15.2.9. AstraZeneca
15.2.9.1. Company Overview
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Business Strategies
15.2.9.5. Recent Developments
List of Tables
Table 01: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 02: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 03: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 05: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 06: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 07: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 08: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 11: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 12: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 15: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 16: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 19: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 20: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Drug Type, 2020-2034
Table 23: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Indication Type, 2020-2034
Table 24: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global Proton Pump Inhibitors (PPIs) Market Value Share, by Drug Type, 2023
Figure 03: Global Proton Pump Inhibitors (PPIs) Market Value Share, by Indication Type, 2023
Figure 04: Global Proton Pump Inhibitors (PPIs) Market Value Share, by End-user, 2023
Figure 05: Global Proton Pump Inhibitors (PPIs) Market Value Share, by Region, 2023
Figure 06: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 07: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Drug Type, 2023
Figure 08: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Drug Type, 2034
Figure 09: Global Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 10: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Omeprazole, 2020-2034
Figure 11: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Omeprazole, 2023 and 2034
Figure 12: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Pantaprazole, 2020-2034
Figure 13: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Pantaprazole, 2023 and 2034
Figure 14: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Esomeprazole, 2020-2034
Figure 15: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Esomeprazole, 2023 and 2034
Figure 16: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Lansoprazole, 2020-2034
Figure 17: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Lansoprazole, 2023 and 2034
Figure 18: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Rabeprazole, 2020-2034
Figure 19: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Rabeprazole, 2023 and 2034
Figure 20: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Others, 2020-2034
Figure 21: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Others, 2023 and 2034
Figure 22: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 23: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Indication Type, 2023
Figure 24: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Indication Type, 2034
Figure 25: Global Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 26: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Gastroesophageal Reflux Disease, 2020-2034
Figure 27: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Gastroesophageal Reflux Disease, 2023 and 2034
Figure 28: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Peptic Ulcers, 2020-2034
Figure 29: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Peptic Ulcers, 2023 and 2034
Figure 30: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 31: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Distribution Channel, 2023
Figure 32: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Distribution Channel, 2034
Figure 33: Global Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 34: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Hospitals Pharmacies, 2020-2034
Figure 35: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Hospitals Pharmacies, 2023 and 2034
Figure 36: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Retail Pharmacies, 2020-2034
Figure 37: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Retail Pharmacies, 2023 and 2034
Figure 38: Global Proton Pump Inhibitors (PPIs) Market Value (US$ Mn), by Online Pharmacies, 2020-2034
Figure 39: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Online Pharmacies, 2023 and 2034
Figure 40: Global Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Region, 2023 and 2034
Figure 41: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Region, 2023
Figure 42: Global Proton Pump Inhibitors (PPIs) Market Share Analysis, by Region, 2034
Figure 43: Global Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Region, 2023-2034
Figure 44: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 45: North America Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Country, 2023 and 2034
Figure 46: North America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Country, 2024-2034
Figure 47: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 48: North America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 49: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 50: North America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 51: North America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 52: North America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 53: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 54: Europe Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 55: Europe Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 57: Europe Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 58: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 59: Europe Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 60: Europe Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 61: Europe Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 62: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 63: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 64: Asia Pacific Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 65: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 66: Asia Pacific Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 67: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 68: Asia Pacific Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 69: Asia Pacific Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 70: Asia Pacific Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 71: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 72: Latin America Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 73: Latin America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 74: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 75: Latin America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 76: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 77: Latin America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 78: Latin America Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 79: Latin America Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 80: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 81: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 82: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 83: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Drug Type, 2023 and 2034
Figure 84: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Drug Type, 2024-2034
Figure 85: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Indication Type, 2023 and 2034
Figure 86: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 87: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 88: Middle East & Africa Proton Pump Inhibitors (PPIs) Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Proton Pump Inhibitors (PPIs) Market
